Biogen (NASDAQ:BIIB) Issues FY 2026 Earnings Guidance

Biogen (NASDAQ:BIIB) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share guidance of 15.250-16.250 for the period, compared to the consensus earnings per share estimate of 14.940. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on BIIB shares. Wedbush lifted their price target on Biogen from $143.00 to $178.00 and gave the company a “neutral” rating in a research note on Friday, January 23rd. Piper Sandler reaffirmed a “neutral” rating and issued a $157.00 target price (up from $118.00) on shares of Biogen in a report on Friday, November 21st. Sanford C. Bernstein set a $191.00 price objective on Biogen in a research note on Tuesday. Robert W. Baird lowered their target price on Biogen from $255.00 to $250.00 in a report on Friday, October 31st. Finally, Stifel Nicolaus raised Biogen from a “hold” rating to a “buy” rating and lifted their price target for the stock from $144.00 to $202.00 in a research note on Thursday, November 6th. Eleven equities research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $192.58.

Biogen Trading Up 8.5%

Biogen stock traded up $15.82 during trading on Friday, hitting $201.18. The company’s stock had a trading volume of 3,403,175 shares, compared to its average volume of 1,664,618. The stock’s fifty day moving average is $176.55 and its 200 day moving average is $156.12. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.04 and a current ratio of 2.72. Biogen has a 1-year low of $110.04 and a 1-year high of $202.41. The stock has a market capitalization of $29.51 billion, a price-to-earnings ratio of 18.34, a P/E/G ratio of 1.56 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.27. Biogen had a net margin of 15.98% and a return on equity of 14.13%. The company had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the prior year, the company posted $3.44 EPS. The company’s quarterly revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, equities research analysts predict that Biogen will post 15.83 EPS for the current year.

Insider Buying and Selling at Biogen

In other Biogen news, insider Priya Singhal sold 748 shares of Biogen stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $179.30, for a total transaction of $134,116.40. Following the sale, the insider directly owned 6,271 shares in the company, valued at $1,124,390.30. The trade was a 10.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.18% of the stock is owned by corporate insiders.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 earnings and sales beat estimates — Biogen posted $1.99 EPS vs. consensus ~ $1.72 and revenue of $2.28B vs. ~$2.21B, giving investors confidence in near-term profitability. BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat ’26 EPS View
• Positive Sentiment: Leqembi and other newer therapies are driving growth — management noted pickup in Leqembi demand and strong sales from Skyclarys and Zurzuvae that helped offset MS declines. Biogen Hits 52-Week High, Alzheimer’s Drug Sales Jump
• Positive Sentiment: FY2026 EPS guidance topped street expectations — Biogen set adjusted EPS guidance of $15.25–16.25, above consensus (~$14.94), supporting a higher valuation multiple despite revenue pressure. Biogen forecasts annual profit above estimates as Leqembi sales pick up
• Positive Sentiment: Analyst support — recent analyst upgrade/buy coverage (e.g., RBC) is reinforcing investor demand following the beats and guidance. Biogen (BIIB) Receives a Buy from RBC Capital
• Neutral Sentiment: Company materials available — press release, slide deck and conference call are posted for investors to review details behind the beat and guidance (useful for Q&A and modeling). View Press Release / Slide Deck
• Negative Sentiment: MS portfolio pressure remains — revenue was down year-over-year and management expects continued declines in MS therapies as generics/competition weigh on legacy sales, a risk to top-line growth. Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. CIBC Private Wealth Group LLC boosted its holdings in shares of Biogen by 8.1% in the third quarter. CIBC Private Wealth Group LLC now owns 1,189 shares of the biotechnology company’s stock worth $167,000 after buying an additional 89 shares during the period. CIBC Bancorp USA Inc. purchased a new position in Biogen during the 3rd quarter worth approximately $3,585,000. Captrust Financial Advisors raised its stake in Biogen by 13.3% during the 3rd quarter. Captrust Financial Advisors now owns 16,532 shares of the biotechnology company’s stock valued at $2,316,000 after purchasing an additional 1,937 shares during the period. Coldstream Capital Management Inc. lifted its holdings in shares of Biogen by 38.0% in the third quarter. Coldstream Capital Management Inc. now owns 4,480 shares of the biotechnology company’s stock valued at $628,000 after purchasing an additional 1,234 shares in the last quarter. Finally, Danske Bank A S acquired a new stake in shares of Biogen in the third quarter worth $6,263,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.